MedPath

A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache

Phase 3
Completed
Conditions
Episodic Cluster Headache
Registration Number
NCT00033839
Lead Sponsor
Winston Laboratories
Brief Summary

This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active ingredients).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (26)

Valley Neurological Headache & Research Center

🇺🇸

Phoenix, Arizona, United States

Neurological Associates of Tucson

🇺🇸

Tucson, Arizona, United States

Northern California Headache Clinic

🇺🇸

Mountain View, California, United States

San Francisco Clinical Research Center

🇺🇸

San Francisco, California, United States

California Medical Clinic for Headache

🇺🇸

Santa Monica, California, United States

New England Center for Headache, PC

🇺🇸

Stamford, Connecticut, United States

Neurology Clinical Research, Inc.

🇺🇸

Plantation, Florida, United States

Neurology and Headache Specialists of Atlanta

🇺🇸

Decatur, Georgia, United States

Diamond Headache Clinic

🇺🇸

Chicago, Illinois, United States

Boston Clinical Research Center

🇺🇸

Wellesley Hills, Massachusetts, United States

Scroll for more (16 remaining)
Valley Neurological Headache & Research Center
🇺🇸Phoenix, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.